Evaluation of in vitro activity of delafloxacin against Staphylococcus aureus MSSA and MRSA isolated from a Brazilian tertiary hospital
Patricia Orlandi Barth, Laura Ribas Ucha, Larissa Lutz, Afonso Luís Barth · 2026
Read Evaluation of in vitro activity of delafloxacin against Staphylococcus aureus MSSA and MRSA isolated from a Brazilian tertiary hospital by Patricia Orlandi Barth, Laura Ribas Ucha, Larissa Lutz, Afonso Luís Barth (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13575000.txt.
Description
Patricia Orlandi Barth and co-authors test, in a 2026 study, a new antibiotic against staph bacteria taken from a Brazilian hospital. Staphylococcus aureus, above all its drug-resistant MRSA form, is a stubborn cause of hospital infections. The drug, delafloxacin, attacks a broad range of bacteria. The team gathered one hundred seventeen isolates from skin, airways, and blood, split between drug-sensitive and resistant strains.
Response to the drug varied by where the bacteria came from. Skin and soft tissue isolates answered best, while airway isolates answered worst. Blood isolates were held back at low drug levels across the board. A fingerprinting method showed the strains were a diverse mix, not one outbreak clone. The authors say the drug looks like a good option for staph infections, with the source of the sample worth weighing.
Catalog record
| CREATOR | Patricia Orlandi Barth, Laura Ribas Ucha, Larissa Lutz, Afonso Luís Barth |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |